Cyclo Therapeutics Inc. Watch

from S-1/A 41 pages Cyclo Therapeutics, Inc. [●] Shares of Common Stock Pre-Funded Warrants to Purchase Up to [●] Shares of Common Stock Warrants to Purchase Up to [●] Shares of Common Stock Underwriting Agreement

from 8-K 42 pages 1,950,000 Shares of Common Stock of Cyclo Therapeutics, Inc. Underwriting Agreement

from 8-K 49 pages 2,500,000 Shares of Common Stock and 2,500,000 Warrants to Purchase 2,500,000 Shares of Common Stock of Cyclo Therapeutics, Inc. Underwriting Agreement

from S-1/A 46 pages Shares of Common Stock and Warrants to Purchase Shares of Common Stock of Cyclo Therapeutics, Inc. Underwriting Agreement

from 10KSB 1 page [Letterhead of James Moore & Co.] Independent Auditors' Report to the Board of Directors and Stockholders of Cyclodextrin Technologies Development, Inc.: We Have Audited the Accompanying Balance Sheet of Cyclodextrin Technologies Development, Inc. as of December 31, 1998, and the Related Statements of Operations, Comprehensive Income, Stockholders' Equity and Cash Flows for the Years Ended December 31, 1998 and 1997. These Financial Statements Are the Responsibility of the Company's Management. Our Responsibility Is to Express an Opinion on These Financial Statements Based on Our Audit. We Conducted Our Audit in Accordance With Generally Accepted Auditing Standards. Those Standards Require That We Plan and Perform the Audit to Obtain Reasonable Assurance About Whether the Financial Statements Are Free of Material Misstatement. an Audit Includes Examining, on a Test Basis, Evidence Supporting the Amounts and Disclosures in the Financial Statements. an Audit Also Includes Assessing the Accounting Principles Used and Significant Estimates Made by Management, as Well as Evaluating the Overall Financial Statement Presentation. We Believe That Our Audit Provides a Reasonable Basis for Our Opinion. in Our Opinion, the Financial Statements Referred to Above Present Fairly, in All Material Respects, the Financial Position of Cyclodextrin Technologies Development, Inc. as of December 31, 1998, and the Results of Its Operations and Its Cash Flows for the Years Ended December 31, 1998 and 1997, in Conformity With Generally Accepted Accounting Principles. /S/ January 28, 1999 Gainesville, Florida F - 1

from 10KSB 1 page [Article] 5 [Legend] This Schedule Contains Summary Financial Information Extracted From Financial Statements for the 12 Months Ended December 31, 1996, and Is Qualified in Its Entirety by Reference to Such Form 10ksb for Year Ended December 31, 1996. [Multiplier] 1 <table> <s> <c> [Period-Type] 12 Mos [Fiscal-Year-End] Dec-31-1996 [Period-End] Dec-31-1996 [Cash] 7,767 [Securities] 0 [Receivables] 106,192 [Allowances] 0 [Inventory] 76,379 [Current-Assets] 356,260 [PP&E] 73,728 [Depreciation] 41,435 [Total-Assets] 654,100 [Current-Liabilities] 62,242 [Bonds] 0 [Common] 120 [Preferred-Mandatory] 0 [Preferred] 0 [Other-Se] 583,425 [Total-Liability-And-Equity] 654,100 [Sales] 344,068 [Total-Revenues] 346,700 [Cgs] 45,354 [Total-Costs] 300,599 [Other-Expenses] 14,646 [Loss-Provision] 0 [Interest-Expense] 0 [Income-Pretax] (13,899) [Income-Tax] 229,350 [Income-Continuing] 215,451 [Discontinued] 0 [Extraordinary] 0 [Changes] 0 [Net-Income] 215,451 [EPS-Primary] .19 [EPS-Diluted] .19 </Table>